Once-weekly Basal insulin Icodec shows similar efficacy to Glargine

      Insulin icodec is an experimental basal insulin analogue which is used to maintain normal blood glucose in type 2 patients (T2DM). In a phase 2 study, insulin icodec was found better than other insulin therapies for type 2 patients.

A 26- week trial that involved 247 adults with T2DM who have not previously been prescribed insulin, inadequately controlled (HbA1c 7.0–9.5%) was conducted to examine the efficacy and safety of icodec. One set of subjects were randomized to once-weekly insulin icodec and the other set were randomized to once-daily insulin glargine U100. The primary endpoint showed that the change from baseline to week 26 in blood sugar control (HbA1c) was similar in participants receiving once-weekly insulin icodec compared to once-daily insulin glargine U100 (-1.33% vs -1.15% points, respectively, p=0.08). Secondary endpoints included change in fasting plasma glucose (FPG) from baseline to week 26, which was similar for insulin icodec and insulin glargine U100 (-58mg/dL and -54mg/dL respectively), and the change from baseline to week 26 of the mean of the nine-point self-monitoring of blood glucose (SMBG) profile, which was greater for icodec (-7.9 mg/dL; p= 0.01).

The study showed that insulin icodec was on par with insulin glargine in terms of lowering blood sugar and safety protocol.

Read More

Freestyle Libre 3 system

      A new device in Continuous Glucose Monitoring, after Libre pro, Libre and Libre 2, the ‘FreeStyle Libre 3 system’ automatically delivers real-time, up-to-the-minute glucose readings, unsurpassed 14-day accuracy and optional glucose alarms directly to smartphones for people with diabetes. Libre 3 is the thinnest and smallest continuous glucose monitor in the world, at the size of two stacked U.S. pennies. The price of the sensor has not changed

      The FreeStyle Libre 3 system is designed to fit seamlessly into people's lives, enabling users to discreetly check their glucose as often as they like without having to fingerstick. This is a life-changing innovation that lets people live better and gain deeper understanding of their glucose levels.

      The sensor is self-applied to the skin on the back of the upper arm. Users can set up alarms on their smartphone so that they can be alerted when glucose levels are out of range, and can take a look at their phone at any time for a real-time glucose reading, which is updated every minute. The self-applied sensor provides readings for up to 14 days, which is longer than many other CGMs on the market.